Member Sign In

You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating indiv idual securities.

If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.

The Zacks Research Daily presents the best research output of our analyst team. Today's Research Daily features new research reports on 16 major stocks, including Royal Dutch Shell (RDS.A), Morgan Stanley (MS) and Aetna (AET). These research reports have been hand-picked from the roughly 70 reports published by our analyst team today.

Royal Dutch Shell shares are up +12.6% so far in 2017 vs. the +1.8% gain for the Zacks Integrated Oil industry. The integrated behemoth's upstream unit have benefited from the steady oil recovery, while production contribution of BG assets continues to be strong.

The supermajor has also been able to reduce operating costs and progress on its large divestment program. Importantly, the company generated a surge in cash flows during the most recent quarter, allowing it to cut debt and cover its cash dividend.

However, with oil unable to stay above the psychologically-critical $50 threshold for more than a few days, Shell's near-to-medium term revenue outlook remains cloudy. The Zacks analyst is also apprehensive that the group's disposal program could affect production, which fell 11% sequentially in second quarter. Hence, the analyst advises investors to wait for a better entry point before buying shares in Europe's largest oil company.

Morgan Stanley's shares have outperformed the Zacks Investment Bank industry, over the last six months (+20.8% vs. +16.4%). The performance was supported by the company’s impressive earnings surprise history. It surpassed the Zacks Consensus Estimate for earnings in all the trailing four quarters.

The company’s efforts to offload its non-core assets to lower balance sheet risk and cost saving initiatives (Project Streamline) will likely lead to improvement in profitability. However, continued fall in corporate loan balances remains a near-term concern. This is significantly hurting the company's interest income growth.

Buy-rated Aetna’s shares outperformed the Zacks Health Maintenance Organization industry year to date, increasing +26% vs. a gain of +24.7%. The Zacks analyst expects the company to derive long-term growth from its Government business. Cost-reduction initiatives and growing ACO collaborations pave the way for long-term growth.

A strong balance sheet is another positive. Its International expansion is also perceived as an opportunity in the face of increased regulation in the U.S. Following strong second-quarter results, Aetna rasied its earnings guidance which cements investors' confidence in the company. The stock has seen the Zacks Consensus Estimate for current-year earnings being revised 6.3% upward over the last 90 days.

Aetna has, however, been incurring losses in its public exchange business and has been exiting exchanges to avoid losses from this business. Furthermore, its membership growth remains under pressure. Increasing medical benefit ratios are also likely to hurt margins.

Other noteworthy reports we are featuring today include Johnson Controls International (JCI), CSX (CSX) and LyondellBasell Industries (LYB).

Can Hackers Put Money INTO Your Portfolio?

Earlier this month, credit bureau Equifax announced a massive data breach affecting 2 out of every 3 Americans. The cybersecurity industry is expanding quickly in response to this and similar events. But some stocks are better investments than others.

Zacks has just released Cybersecurity! An Investor’s Guide to help Zacks.com readers make the most of the $170 billion per year investment opportunity created by hackers and other threats. It reveals 4 stocks worth looking into right away.

Note: Sheraz Mian heads the Zacks Equity Research department and is a well-regarded expert of aggregate earnings. He is frequently quoted in the print and electronic media and publishes the weekly Earnings Trendsand Earnings Preview reports. If you want an email notification each time Sheraz publishes a new article, please click here>>>

Resources

Client Support

Follow Us

Zacks Moblie App

Zacks Research is Reported On:

Yahoo

MSN

Marketwatch

Nasdaq

Forbes

Investors.com

Morningstar

Copyright 2018 Zacks Investment Research

At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +25% per year. These returns cover a period from 1988-2017. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zack Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations.

Visit performance for information about the performance numbers displayed above.